Multicenter, Open-label, Non-interventional Study (NIS) to Evaluate Patient's Satisfaction and Preference, the Usability of DuoResp SPIROMAX and the Impact on Clinical Effects, in the Daily Routine of Asthma and COPD Treatment
Phase of Trial: Phase IV
Latest Information Update: 19 Dec 2017
At a glance
- Drugs Budesonide/formoterol (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Teva Pharmaceutical Industries
- 03 Nov 2016 Status changed from active, no longer recruiting to completed.
- 13 Apr 2016 Planned End Date changed from 1 Dec 2016 to 1 Sep 2016.
- 02 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2016 as per ClinicalTrials.gov record.